EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans

Magali Ayala, Alifia Jakamartana, Rodrigo Mamede Dos Santos Costa, Eric Cheuk-Kiu Cheung, Joseph M Bednarek, Christian T Moreau, Jessica C S Brown iD

mSphere · 2026

DOI: 10.1128/msphere.00432-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, 2026. Verfasst von Magali Ayala und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Cryptococcus neoformans, Candida albicans, Drug Synergism. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic fungal infections cause an estimated 3.8 million deaths annually, approximately 10% of which are caused by drug-resistant infections. With only five classes of antifungal drugs, treatment options are limited. Here, we explore synergistic drug combinations—when the efficacy of two drugs combined is greater than expected based on the sum of each individual drug’s efficacy—to improve treatment of drug-resistant Cryptococcus neoformans and Candida albicans . Chlorpromazine acts synergistically with both amphotericin B and fluconazole against multiple fungal species, including azole-resistant C. neoformans and C. albicans . We then performed a genome-wide knockout mutant screen and found that ESCRT pathway mutants are resistant to chlorpromazine, while knockout mutants of genes involved in fatty acid biosynthesis are sensitive. Based on these data, we investigated sterol and fatty acid composition in chlorpromazine-treated cells and found only minor increases in sterol precursors, but a substantial increase in lipid droplet size and decreased lipid droplet numbers. This lipid droplet formation potentially sequesters lipid bioavailability and response to membrane stress. Together, these data suggest that chlorpromazine and its analogs are potentially promising treatments for systemic fungal infections that act via lipid homeostasis and stress response. IMPORTANCE Fungal infections are a large and expensive health burden with high mortality rates. People with compromised immune systems from cancer, solid organ transplant, HIV infection, and other conditions are particularly affected. Systemic fungal infections are difficult to treat because there are few available drugs and treatment periods last months or years. Long treatment times increase the risk of treatment failure and can contribute to the rise of resistance. We identified an additional class of drugs, chlorpromazine and other phenothiazine drugs, that amplify the activity of existing antifungal drugs amphotericin B (AmB) and fluconazole (FLZ). AmB and FLZ act by targeting ergosterol, the fungal equivalent of cholesterol, which is required for a functional plasma membrane. Chlorpromazine increases the formation of lipid drops, which sequester lipids such as ergosterol. When chlorpromazine is combined with AmB, the fungal cell cannot respond to the plasma membrane damage caused by AmB, inhibiting the fungal cells. This work identifies new target processes and drugs that could treat deadly fungal infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCryptococcus neoformansCandida albicansDrug SynergismDrug Resistance, FungalAntipsychotic AgentsChlorpromazineMicrobial Sensitivity TestsAmphotericin BFluconazole

Stichwörter der Autor:innen

antifungal resistancedrug resistancefungal infectionslipid biosynthesis

Substanzen

Antifungal AgentsChlorpromazineAmphotericin BFluconazoleAntipsychotic Agents

Autor:innen und Institutionen

  • School of Biological Sciences, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Jessica C S Brown

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Ayala, M., Jakamartana, A., Costa, R. M. D. S., Cheung, E. C. K., Bednarek, J. M., Moreau, C. T., & Brown, J. C. S. (2026). Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans. mSphere. https://doi.org/10.1128/msphere.00432-26

Vancouver

Ayala M, Jakamartana A, Costa RMDS, Cheung ECK, Bednarek JM, Moreau CT, et al. Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans. mSphere. 2026. doi:10.1128/msphere.00432-26

BibTeX
@article{Ayala2026,
  author = {Ayala, Magali and Jakamartana, Alifia and Costa, Rodrigo Mamede Dos Santos and Cheung, Eric Cheuk-Kiu and Bednarek, Joseph M and Moreau, Christian T and Brown, Jessica C S},
  title = {Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans},
  journal = {mSphere},
  year = {2026},
  doi = {10.1128/msphere.00432-26}
}
Kostenlos starten →